• Services

    Services

    Inoviem provides a full range of services from drug discovery to clinical development by leveraging its platforms and direct access to human pathological specimens.
    All the platforms and services are label-free with no modification of the original molecules.

    Target & MoA Deconvolution
    Target Validation & Engagement

    Lead Compound Selection

    Patient Cohort Stratification

    Indication Prioritization

    Biomarker Discovery

    SPR and Proteomics

    Human Biological Samples Provision

  • Platforms

    Platforms

    Inoviem provides breakthrough protein technologies for each phase of the drug development process.
    One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy

    NPOT®

    Unlocking drug mechanism of action in native biological contexts

    Read more

    PIMS®

    Designed to study molecular interactions and predict therapeutic responses in biomedical research

    Read more

    LIPS

    Designed to measure drug-target interactions with high accuracy in native environments, including cultured cells and patient tissues.

    Read more

    Biomarkers discovery

    Methodology for the proteomic profiling of human individuals in the context of translational evaluation of biomarkers and clinical development of new drug candidates.

    Read more

  • Expertise

    Our expertise in translational pharmacology

    Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies, developed in a pathological and physiological environment, that uses human tissue.

    Translational pharmacology expertise

    Pre-clinical to clinical phases

    Read more

    Our innovative approach

    Biomarkers, patient and therapeutic window

    Read more

    Advantages of approach

    Save time and money

    Read more

    How we work with clients

    Tailored methodologies and technologies 

    Read more

  • Knowledge centre
  • About us

    About us

    Inoviem Scientific is a Bioanalytical R&D company established in 2011 in Strasburg – France.

    Our mission

    Our mission is clear: to get the right treatment to the right patients within the right therapeutic window.

    Read more

    Our team

    • Management team
    • Scientific board
    • Supervisory board & investors

    Read more

  • Contact us

Proteomic profiling for biomarkers discovery in human whole blood and complex human matrixes (serum, plasma, sputum, balf, urine)

Inoviem has developed a sensitive and accurate proteomic methodology for the proteomic profiling of human individuals in the context of translational evaluation of biomarkers and clinical development of new drug candidates. The methodology works with both human frozen whole blood and any other matrixes including plasma/sera, urine, sputum etc.

The workflow of MS-based proteomics experiments includes the following steps: experimental design, sampling, tissue/cell preparation, protein extraction, separation, MS analysis, protein identification, statistical analysis of data, validation of identification, quantification, and data analysis. The experimental design is detailed in a table, which is submitted for approval.

Method for frozen whole blood: 3D fractioning sample preparation

This methodology has the great potential of analyzing frozen whole blood for biomarkers discovery by extracting hemoglobin. Haemoglobin indeed poses a significant challenge in whole blood proteomic analysis due to its high abundance and potential to interfere with the detection of other proteins. Inoviem developed a label free, non-chromatography-based methodology to extract the haemoglobin and to elute the proteins bound to albumin.

The steps for whole blood preparation:

Haemoglobin depletion

Iron ions (Fe2+) are replaced by Mn2+ and Mg2+ with gradually increasing saline forces. This will precipitate free hemoglobin and induce hemagglutination.

Charge distribution-based fractioning

Stepwise change in ionic forces from neutral to acid between with pH interval 4 to 6.

Hydrophobicity-based fractioning

Separation as well as isolation of hydrophobic and hydrophilic proteins using proprietary three phases gradient. Each phase is analyzed thereafter in triplicate.

Size-based fractioning

Filtration on SDS-PAGE gradient gel, isolation of proteins and proceed to proteomics.

Each fractioned phase is sequenced via label-free quantitative proteomics (LC-MS/MS) and the proteins are analyzed both quantitatively and qualitatively.
This method identifies an average of 710 proteins per blood sample, outperforming other depletion and fractionation methods available on the market, which typically rely on labelling and conjugation chemistry approaches.

uman Biological Samples Provision - Inoviem

Qualitative analysis

Label free proteomics analysis reveals many proteins that can be easily sorted and ranked by Inoviem’s InOpera database, able to discriminate between frequent and specific proteins within the dataset. This opens the possibility to perform pathway enrichment analysis aiming to the identification of modulated pathways related to disease features (e.g. progression rate, stage) or to treatment response (e.g. response/non-response related pathways) leading to the identification of potential biomarkers candidates.

Quantitative analysis

Each fractioned blood sample undergoes to label-free quantification in order to get an exhaustive proteomic signature of each patient.

Analyses are based on two steps:

  1. Global differences analysis
    • Protein distribution (cell location)
    • Protein’s physico-chemical properties (hydrophobicity, charge distribution, aliphatic and Boman indexes)
    • Identified peptides (numbers/protein for each group)
  2. Specific protein analysis
    • Enriched/impoverished proteins in patient groups
    • Protein/protein interaction and network structure deciphering
    • Relevance with clinical data

These types of analyses can reveal modulated proteins based on patient’s group therefore revealing potential biomarkers candidates. With this methodology we can get the following types of biomarkers:

  • Disease progression biomarkers: Useful for monitoring the course of the disease.
  • Prognostic biomarkers: Useful for predicting the likely outcome or course of the disease.
  • Diagnostic biomarkers: Useful for identifying the presence of a disease.
  • Therapeutic biomarkers: Useful for predicting response to treatment and personalizing therapy.
To learn more, contact us

Headquarter
Bioparc 2, 850 boulevard Sébastien Brant,
67400 Illkirch-Graffenstaden

CONTACT US


SERVICES
EXPERTISE

Our expertise in translational pharmacology
Advantages of a translational pharmacology approach
How we work with clients

PLATFORMS

NPOT®
PIMS®
LIPS
Biomarkers discovery

KNOWLEDGE CENTER
ABOUT US

Our mission
Our team

PRIVACY POLICY
Need Help